Bétaméthasone (Dipropionate De), Bétaméthasone (Phosphate Sodique De)

—

In supply · Australia

Diprostene, suspension injectable en seringue pré-remplie –

In supply · 🇦🇺 Australia · short in🇫🇷 FR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Bétaméthasone (Dipropionate De), Bétaméthasone (Phosphate Sodique De)
Brand names	Diprostene, suspension injectable en seringue pré-remplie –
Therapeutic category	Auto-created by Agence nationale de sécurité du médicament — Disponibilité scraper
Controlled substance	No
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇫🇷 29 June 2026

medium reported

🇫🇷 12 June 2026

medium reported

🇫🇷 5 May 2026

medium reported

🇫🇷 8 Apr 2026

medium reported

🇫🇷 27 Nov 2025

Shortage resolved

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.